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Mehdi Hamadani, Don M. Benson, Jr., Craig C. Hofmeister, Patrick Elder, William Blum,
Pierluigi Porcu, Ramiro Garzon, Kristie A. Blum, Thomas S. Lin, Guido Marcucci,
Steven M. DevinePatients with chemorefractory aggressive non-Hodgkin’s lymphomas (NHL) generally have poor clinical out-
comes with available therapies. Allogeneic transplantation may be curative, but few studies are available to
guide transplant decision making in this setting. We examined allogeneic transplantation outcomes for 46
patients with chemorefractory, aggressive NHL patients who had either stable disease (SD; n 5 32) or
progressive disease (PD; n5 14), respectively, following last salvage treatment. The median age was 46 years
(range: 22-63 years). Thirty-nine patients received matched sibling allografts, whereas 7 underwent unrelated
donor transplantation. Diagnoses included diffuse large B-cell lymphoma (n 5 18), Burkitt’s lymphoma
(n 5 3), transformed B cell lymphoma (n 5 5), mantle cell lymphoma (n 5 11), and peripheral T cell lym-
phoma (n 5 9). The median number of prior therapies was 3 (range: 2-8). Median follow-up of surviving
patients is 5 years. Five-year overall survival (OS), progression-free survival (PFS), and relapse rate for the
whole cohort (n 5 46) were 38%, 34%, and 35%, respectively. The rate of grade II-IV acute graft-versus-
host disease (aGVHD) was 43%. Of the 33 evaluable patients 75% developed chronic GVHD (cGVHD).
Overall nonrelapse mortality (NRM) rate was 34%. The 5-year OS and PFS rates for patients with SD and
PD were 46% versus 21% (P5 .01; log-rank test), and 46% veruss 7% (P5 .0002; log-rank test), respectively.
This study confirms that allogeneic transplant is curative for a subset of chemorefractory patients with SD.
However, patients with PD had uniformly poor outcomes following allografting with conventional condition-
ing approaches. Given the outcomes seen here in the setting of PD, such patients should proceed with trans-
plant only in the setting of investigational therapy.
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High-dose therapy and autologous hematopoietic
stem cell transplantation (HSCT) is standard therapy
for patients with relapsed chemosensitive diffuse large
B cell lymphoma (DLBCL), and appears to be curative
for 40% to 45% of the patients [1-3]. Relapsedematology andOncology, Arthur G. James Comprehen-
ancer Center, The Ohio State University, Columbus,
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6/j.bbmt.2009.01.010non-Hodgkin lymphoma (NHL) patients with other
aggressive histologies including peripheral T cell lym-
phoma (PTCL), transformed B cell lymphoma, mantle
cell lymphoma (MCL), and Burkitt lymphoma (BL),
generally do not achieve sustained remissions follow-
ing autologous transplantation [4-8]. Results of autol-
ogous HSCT in the high-risk group of relapsed
aggressive NHL patients who are refractory to salvage
chemotherapy have been uniformly disappointing.
Allogeneic HSCT is a potentially curative modality
for a number of hematologic malignancies, including
indolent and aggressive lymphomas [9-11]. The
advantages of an allogeneic graft include a tumor-
free graft, and a potential immune-mediated graft-
versus-lymphoma (GVL) effect.
Despite the inherent risk of increased transplant-
relatedmorbidity andmortality (TRM) associatedwith
allogeneic HSCT, select relapsed aggressive NHL
patients, especially the subgroup with chemosensitive547
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allografting [11-16]. Aggressive NHL patients who
are refractory to salvage chemotherapy have poor
prognosis. There are only limited data available about
the outcomes following allogeneic HSCT for this
extremely poor-risk group. We describe here the out-
comes of chemorefractory aggressive NHL patients
with mature follow-up undergoing allogeneic trans-
plantation at our institution.PATIENTS AND METHODS
Patient Population
Patients with a history of histologically confirmed
aggressive NHL undergoing allogeneic HSCT were
identified from a prospectively maintained database
of all patients undergoing HSCT at Ohio State Uni-
versity. Acceptable histologies included DLBCL, BL,
transformed B cell lymphoma, PTCL, and MCL
[17-19]. Patients with a diagnosis of indolent lym-
phoma and those with lymphoblastic lymphoma were
not included in this study. Patients undergoing alloge-
neic transplantation with an untreated relapse (i.e.,
patients not receiving salvage chemotherapy before
transplant) were also excluded. For aggressive NHL
patients receiving salvage chemotherapy before trans-
plantation, response to salvage therapy was assessed
according to standard criteria [20]. Patients achieving
partial response (PR) or complete response (CR) to
salvage chemotherapy were considered to have chemo-
sensitive disease and were excluded from this analysis.
Those patients with an available normal gallium or
PET (positron emission tomography)-scan before
transplantation (regardless of the presence or absence
of residual radiographic abnormalities on CT scans)
were also excluded. Aggressive NHL patients who
had chemorefractory disease (i.e., patients with stable
disease [SD] or progressive disease [PD]) as specified
by Cheson et al.’s [20] criteria following salvage che-
motherapy, constitute the subject of this study.Transplantation Procedure and Supportive Care
All patients were treated in HEPA-filtered inpa-
tient bone marrow transplantation unit, and received
fungal, herpes zoster, bacterial, and Pneumocystis jiro-
veci prophylaxis. Patients and their donors were tested
for HLA-A, HLA-B, and HLA-C by at least standard
serologic typing and for HLA-DRB1 by high-
resolution techniques. Unmanipulated hematopoietic
stem cells (HSCs; mobilized from peripheral blood
or harvested from nonstimulated marrow) were in-
fused through a central venous catheter on day zero.
Allogeneic HSCT recipients were monitored weekly
for cytomegalovirus (CMV) reactivation with hybrid
capture assay. Ganciclovir or foscarnet were used atthe discretion of treating physician for patients with
evidence of CMV reactivation. All patients received
irradiated and leukoreduced blood products. CMV
negative products were used for CMV seronegative
patients. Neutrophil engraftment was defined as first
of 3 successive days with ANC $0.5  109/L after
posttransplantation nadir. Platelet engraftment was
considered to have occurred on the first of 3 consecu-
tive days with a platelet count of 20 109/L or higher,
in the absence of platelet transfusion. Graft-versus-
host disease (GVHD) was graded using standard crite-
ria [21]. Patients achieving neutrophil engraftment
were evaluable for acute GVHD (aGVHD), whereas
patients surviving at least 100 days posttransplantation
were evaluable for chronic GVHD (cGVHD).
Post-HSCT Monitoring
Patients underwent restaging bone marrow aspira-
tion and biopsy (if abnormal before transplantation)
and computed tomography of the chest, abdomen,
and pelvis on day160 (or earlier if clinically indicated)
after HSCT. Imaging studies were repeated at 3
monthly intervals for first 3 years and annually
thereafter through 5 years after HSCT. All post-
transplant radiographic studies were retrospectively
reviewed and responses assessed according to standard
criteria [20]. In the ambulatory setting (postallograft-
ing), patients were followed at least weekly until day
190, then every 4 to 6 weeks up to day1180, followed
by outpatient visits at least every 12 weeks until 3 years
posttransplantation. Relapse or disease progression
was histologically confirmed (when possible). Donor
lymphocyte infusions (DLIs) were not routinely
performed in patients with persistent disease or relapse
posttransplantation.
Data Collection and Statistical Analysis
Data were collected using retrospective chart and
database review. All available pathologic, radiologic,
and autopsy reports were reviewed. Overall survival
(OS) and progression-free survival (PFS) were esti-
mated using the Kaplan-Meier method. OS was
defined as the time from transplant to death from
any cause, and surviving patients were censored at
last follow-up. PFS from transplantation was calcu-
lated using death and disease progression and/or
relapse as events. Nonrelapse mortality (NRM) was
defined as death from any cause other than disease pro-
gression or relapse. Cumulative incidence was esti-
mated for NRM and relapse risk, with relapse as
a competing risk for the former and death in remission
for the latter. Gary’s test was used to assess the differ-
ence between various subgroups for NRM and relapse
rate. All calculations were performed using the SPSS
13.0 statistical package (SPSS Inc, Chicago, IL), except
competing risk analysis for the cumulative incidence of
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R-Project (version 2.8.0; http://www.r-project.org/).
All P-values are 2 sided.RESULTS
Patient Characteristics
One hundred eight patients with aggressive NHL
underwent allogeneic HSCT between 1988 and 2007
at our institution. Forty-six patients with chemorefrac-
tory disease following salvage chemotherapy, under-
going allogeneic transplantation between 1994 and
2007, met the inclusion criteria of this study. The
median age was 46 years (range: 22-63 years). Median
Karnofsky performance status at the time of transplan-
tation was 90 (range: 60-100). Thirty-nine patients
received matched sibling allografts, whereas 7 under-
went unrelated donor SCT. All except 3 patients
received myeloablative conditioning. Histologic diag-
nosis (confirmed by review at Ohio State University)
included DLBCL (n 5 18), BL (n 5 3), transformed
B cell lymphoma (n 5 5), MCL (n 5 11), and PTCL
(n 5 9). The median number of prior therapies was 3
(range: 2-8). No patient previously underwent autolo-
gous HSCT. At the time of transplantation 41 (89%)
patients had advanced stage (Ann Arbor stage III/IV)
disease, 23 (50%) patients had elevated lactate dehy-
drogenase (LDH), 36 (78%) had extranodal involve-
ment, whereas 14 (30%) patients had bulky disease
(lymph nodes .5 cm). Among the patients with bulky
disease 8 had SD, whereas 6 had PD (P 5 .22) before
allografting. Four patients (9%) had central nervous
system (leptomeningeal), and 29 (63%) had bone mar-
row involvement at the time of transplantation. None
of the patients were positive for human immunodefi-
ciency virus (HIV) or human T cell-lymphotropic
virus.Response to Salvage Therapy
At the time of allogeneic HSCT, of the 46 patients
with chemorefractory disease following salvage che-
motherapy, 32 patients had SD, whereas 14 patients
had PD according to standard criteria [20]. Table 1
compares the baseline characteristics of chemorefrac-
tory patients with SD or PD at the time of transplan-
tation. Five patients had PD following salvage
chemotherapy because of development of (histology
confirmed) new lesions. Patients in the SD or PD
groups were comparable in terms of patient age, dis-
ease stage, histologies, stem cell source, CD34 dose,
T cell dose, and GVHD prophylaxis regimen. Patients
with SD were more heavily pretreated (median
number of therapies 4) compared to PD patients (me-
dian number of therapies 2), whereas a higher propor-
tion of patients in PD had elevated LDH. Thirty-onepercent (n5 10) of B cell lymphoma patients in the SD
group and 21% (n 5 3) in the PD group had not pre-
viously received rituximab with salvage chemotherapy
(P5 .49). All patients with SD received myeloablative
conditioning, whereas 3 patients with PD had
reduced-intensity conditioning (RIC).
Transplantation Outcomes
Median follow-up of surviving patients following
allogeneicHSCT is 5 years.Median time to neutrophil
and platelet engraftment was 14 days and 22 days,
respectively. Rate of grade II-IV aGVHD was 43%
(n 5 20) overall, and 35% (n 5 5) and 46% (n 5 15)
in the PD group and the SD group (P 5 .48), respec-
tively (Table 2). Among the 33 evaluable patients,
rate of cGVHD was 75% overall. In patients with
PD and SD, rates of cGVHD were 52% (7 evaluable
patients), and 80% (26 evaluable patients), respectively
(P5 .19). The cumulative incidence ofNRM at 5 years
in the SD group and PD group was 29% (n5 10), and
43% (n 5 6) (P 5 0.24; Gray’s test), respectively. The
corresponding day 100 NRM rates were 9% and 43%,
respectively. In the PD group, causes of death included
disease progression (n5 5), pulmonary failure (n5 2),
aGVHD (n 5 1), pulmonary aspergillosis with
aGVHD (n 5 1), sepsis (n 5 1), and veno-occlusive
disease (VOD) (n 5 1). Causes of death among the
SD group were disease progression (n 5 8), sepsis
with (n 5 2) and without GVHD (n 5 3), pulmonary
failure (n 5 1), GVHD (n 5 2), and VOD
(n 5 2).
Response Rates and Survival
FollowingHSCT the rates of CR, PR, SD, and PD
in patients with PD at the time of transplantation were
21% (n 5 3), 7% (n 5 1), 36% (n 5 5), and 36%
(n 5 5), respectively (Table 2). The response rates in
the SD group in similar order were 65% (n 5 23),
16% (n 5 3), 13% (n 5 4), and 6% (n 5 2). Overall
response rate (CR 1 PR) was markedly superior in
SD group compared to the PD group (81% versus
28%, respectively; P 5 .0005). Immunosuppressive
medications were withdrawn in 2 PD group patients
at the time of disease progression. In the first patient
with anaplastic large cell lymphoma (who initially
entered CR after HSCT), tapering immunosuppres-
sion at the time of histologically proven relapse on
day 1310, produced a second CR lasting 7 months.
In the second patient with angioimmunoblastic lym-
phoma, discontinuation of immunosuppressive at the
time of disease progression (day 1120) did not induce
any GVL effect. Another patient in the PD group
received DLI at the time of disease relapse, which pro-
duced a CR lasting 111 months. DLI was given to 2
patients in the SD group. The first patient received
DLI because of secondary graft failure, and remains
Table 1. Patient Characteristics at the Time of Allogeneic Transplantation
Stable Disease Group Progressive Disease Group
N 5 32 (%) N 5 14 (%) P-Value
Median age,
years (range)
47 (22-59) 44 (29-63) >.05
Sex (male/female) 24/8 10/4 >.05
Stage
I-II 2 (60) 3 (22) >.05
III-IV 30 (93) 11 (78)
B symptoms 17 (53) 10 (71) >.05
LDH
Normal 19 (59) 4 (29) .05
High 13 (41) 10 (71)
Age adjusted
International Prognostic Index
Low or low/intermediate 13 (41) 4 (29) >.05
High or high/intermediate 19 (59) 10 (71)
Donor source
HLA-matched sibling 27 (84) 10 (71) >.05
HLA-matched unrelated 4 (13) 3 (22)
HLA-mismatched related 1 (3) 1 (7)
Diagnosis
Diffuse large B cell lymphoma 11 (34) 7 (50) >.05
Mantle cell lymphoma 10 (31) 1 (7)
Peripheral T cell lymphoma 4 (13) 5 (35)
Transformed B cell lymphoma 4 (13) 1 (7)
Burkitt lymphoma 3 (9) –
Median number
of therapies before HSCT (range)
4 (3-6) 2 (2-8) .02
Median CD34+ cell dose
(106 cells/kg recipient wt)
5.44 4.82 >.05
Median CD3+ cell dose
(108 cells/kg recipient wt)
2.76 2.66 >.05
Myeloablative conditioning
Yes 32 (100) 11 (78) .02
No – 3 (22)
Conditioning regimen
Bu/Cy based 27 (84) 11 (78) >.05
Flu/Bu based – –
Others 5 (16) 3 (22)
Stem cell source
Bone marrow 18 (56) 10 (71) >.05
Peripheral blood 14 (44) 04 (29)
Graft-versus-host disease prophylaxis
Methotrexate/Cyclosporine 23 (71) 11 (78) >.05
Methotrexate/Tacrolimus 9 (29) 3 (22)
Bu/Cy indicates busulphan/cyclophosphamide; Flu/Bu: fludarabine/busulfan; HLA: human leukocyte antigen; HSCT: hematopoietic stem cell transplan-
tation; LDH: lactate dehydrogenase; NHL: non-Hodgkin lymphoma.
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given DLI because of persistent disease after trans-
plantation, which produced a CR lasting 4 months.
At last follow-up, 3 patients in PD group are alive.
Two patients are currently in remission (with no active
cGVHD), whereas the third patient (on immunosup-
pression for extensive cGVHD) is currently undergo-
ing chemotherapy after disease relapse. Interestingly
all 3 surviving patients in the PD group received RIC
at the time of transplantation. None of the patients
undergoing myeloablative conditioning survived be-
yond 6 months post-HSCT. Fourteen SD group
patients are currently alive and all have no evidence
of disease. Four patients are currently on immunosup-
pressive medications for extensive cGVHD. Among
the 4 patients with active leptomeningeal involvement
before myeloablative transplantation, 1 patient is aliveand in remission 9 years posttransplantation, 2 patients
died at 5 and 6 months posttransplant because of dis-
ease progression, whereas the fourth patient died at 3
months postallografting, while in remission secondary
to pulmonary aspergillosis. The 5-year actuarial OS,
PFS, and relapse rate for the whole cohort (n 5 46)
were 38%, 34%, and 35%, respectively. Cumulative
incidence of disease relapse was higher in patients
with PD compared to patients with SD (50% versus
25%; P 5 .08). The 5-year OS and PFS rates for
patients with SD and PD were 46% versus 21%
(P 5 .01; log-rank test) (Figure 1), and 46% versus
7% (P 5 .0002; log-rank test) (Figure 2), respectively.
Fve-year OS for patients with DLBCL, PTCL,
MCL, BL, and transformed B cell lymphoma was
38%, 33%, 18%, 33%, and 100%, respectively. Five-
year PFS in similar order was 38%, 22%, 18%, 33%,
Table 2. Transplant Outcomes of Chemorefractory Patients undergoing Allogeneic Transplantation
Stable Disease Group Progressive Disease Group
P-ValueN 5 32 (%) N 5 14 (%)
Acute GVHD 15 (46%) 5 (35%) .48
Chronic GVHD 21 (80%) 4 (57%) .19
Relapse rate 25% 50% .08†
Nonrelapse mortality 29% 43% .24†
Progression-free survival (5 year) 46% 7% .0002
Overall survival (5 year) 46% 21% .01
Response rates
Overall response rate 26 (81%) 4 (28) .0005*
Complete remission 21 (65%) 3 (21%)
Partial remission 5 (16%) 1 (7%)
Stable disease 4 (13%) 5 (36%)
Progressive disease 2 (6%) 5 (36%)
GVHD indicates graft-versus-host disease.
*P-value is for the difference of overall response rate (complete remission + partial remission) between the 2 groups.
†P-values calculated by Gray’s test.
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PTCL, MCL, BL, and transformed B cell lymphoma
was 38%, 33%, 55%, 0%, and 0%, respectively. Re-
lapse rates for these patients in identical order were
24%, 44%, 27%, 66%, and 20%. Development of
cGVHD was not associated with OS (P 5 .7), PFS
(P 5 .5), or lower relapse rates (P 5 .6).
To address the patient selection bias inherently
associated with evolving transplantation practices
over time, and the general advances in supportive
care, outcomes of patients transplanted between
1994 and 2000 (group O; n 5 20) were compared
with those transplanted between 2001 and 2007 (group
N; n5 26). The 5-year OS for patients in group O and
group N was 40% and 38% (P 5 .99), respectively.
Five-year PFS in similar order was 40% and 30%
(P5 .70), respectively. Onmultivariate logistic regres-
sion analysis, PD at the time of transplantation was the
only variable predictive for inferior PFS (P5 .03), but
not inferior OS (P 5 .19).Figure 1. Kaplan-Meier estimates of OS following allogeneic transplan-
tation (solid curve5 stable disease group; interrupted curve5 progres-
sive disease group).DISCUSSION
Allogeneic HSCT remains the sole curative
modality for high-risk relapsed aggressive NHL
patients [11-16]. Studies focusing solely on the out-
comes of patients with chemorefractory disease at the
time of transplantation have not been previously re-
ported. We report here 5-year OS and PFS rates of
38% and 34%, respectively, for patients with chemo-
refractory aggressive lymphomas.
This study highlights the heterogeneity in trans-
plant outcomes for chemorefractory aggressive NHL
patients. The group of patients with SD following sal-
vage chemotherapy in our study had encouraging
5-year OS and PFS rates of 46% each. These results
are quite encouraging, especially in the context of thedismal outcomes of these high-risk patients with stan-
dard chemotherapy or autologous HSCT. Caution,
however, needs to be exercised while interpreting these
results, as patient selection certainly is partly responsi-
ble for these favorable outcomes, because even these
poor prognosis chemorefractory patients with SD
were judged young and healthy enough to undergo
myeloablative allogeneic HSCT. Nonetheless, sur-
vival rates of SD group in this study are comparable
to previous studies reporting allogeneic transplanta-
tion outcomes of relapsed aggressive NHL (with sim-
ilar inherent selection biases) [12-15]. Doocey et al.
[13] reported 5-year OS of 48% in a cohort of 44
aggressive NHL patients (including 9 with chemore-
fractory disease). Similarly, French [14] and Japanese
[12] registry data have reported OS rates of 41% and
42%, respectively, with allografting in aggressive
NHL. Although these studies included patients with
refractory disease, their outcomes were not reported
separately. Interestingly in Doocey et al. [13], the
Figure 2. Kaplan-Meier estimates of PFS following allogeneic trans-
plantation (solid curve 5 stable disease group; interrupted curve 5
progressive disease group).
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significantly different from patients with chemosensi-
tive disease. Inferior OS for chemorefractory patients
was seen in Italian registry data, but that study
included a substantial proportion of patients with
indolent histologies and Hodgkin disease (HD) [9].
The majority of the patients in previously reported
studies of allogeneic transplantation for aggressive
NHL received total body irradiation (TBI)-based con-
ditioning regimens. In contrast, none of the patients in
this study received TBI, which suggests that non-TBI
based conditioning regimens at least produces out-
comes comparable to TBI conditioning in aggressive
NHL following allogeneic HSCT.
Importantly, this study identifies a cohort of chemo-
refractory patients with PD following salvage chemo-
therapy, who, despite receiving mostly myeloablative
transplantation, had dismal 5-year OS and PFS of
21% and 7%, respectively. Patients exhibiting disease
progression despite combination salvage chemotherapy
clearly represent a group with extremely poor progno-
sis, who are unlikely to benefit from allografting and
should be spared the toxicities of donor transplantation.
At the same time, chemorefractory patients with SD
perhaps have a less aggressive disease biology, and, if
transplant eligible, they appear to have at least a reason-
able chance of long-term survival with allogeneic trans-
plantation. This is noteworthy, because these SD
patients have a uniformly poor outcome if they undergo
high-dose therapyand autologous transplantation. Such
divergent outcomes indicate that the encouraging re-
sults of chemorefractory patients in our study are likely
a result of immune-mediated lymphoma eradication,
and are not simply because of the intensity of condition-
ing chemotherapy administered.Because functional im-
aging (positron-emission tomography [PET]-scanning)
or biopsies to confirm active lymphoma were not rou-
tinelyperformed in all the patientswithSD in this study,
it is possible that these favorable outcomes are becauseof a chance inclusion of large proportion of patients
with residual radiographic abnormalities merely repre-
senting ‘‘nonviable lymphoma.’’ However, survival out-
comes of 14 patients in the SD group who had either
a positive PET scan or histology-
confirmed viable lymphoma at the time of transplanta-
tion were comparable to entire group overall (5-year
OS of 45%, compared to 46% in patients without
such evidence).
The overall NRM rate of 34% in this study for
high-risk patients predominantly undergoing myeloa-
blative allogeneic is comparable to previous studies of
myeloablative allogeneic transplantation in aggressive
NHL, where NRM rates have ranged from 20% to
45% [12,13,15,22]. In the modern era of transplanta-
tionNRM rates over 30% even following ablative con-
ditioning are unacceptably high. Reduced-intensity
conditioning (RIC) transplantation is an attractive
modality that has shown impressively low NRM rates
without compromising efficacy in the indolent lym-
phomas [10,23]. However, for patients with relapsed
aggressive lymphomas, NRM rates with RIC alloge-
neic transplantation, with a few exceptions [9,24] have
been surprisingly high (range: 25%-38%) [25-27]. For
patients with chemosensitive disease, OS rates have
been encouraging (45%-80%) [24,27,28]. Information
about outcomes of chemorefractory patients following
RIC is limited, but at least 2 studies suggest signifi-
cantly inferior outcomes of such patients compared to
those with chemosensitive relapse [25,28]. Prospective
trials comparing myeloablative conditioning with RIC
in the setting of chemorefractory aggressive NHL are
unlikely to be performed, and the choice of condition-
ing regimen will continue to largely depend on patient
age, performance status, disease bulk, and physician
preference.
In conclusion, a subgroup of chemorefractory
patients with SD by standard radiographic criteria fol-
lowing salvage chemotherapy can experience favorable
outcomes following allogeneic transplantation and and
should not be excluded solely based on the lack of ev-
idence of chemosensitive disease. Patients with PD
have a dismal prognosis despite allogeneic transplanta-
tion, and should not be considered for allogeneic
transplantation except in the setting of a clinical trial.ACKNOWLEDGMENTS
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